Reuters logo
BRIEF-Pulmatrix says received key patent in U.S. For PUR0200
May 9, 2017 / 3:38 PM / 4 months ago

BRIEF-Pulmatrix says received key patent in U.S. For PUR0200

May 9 (Reuters) - Pulmatrix Inc

* Received key patent in U.S. for its lead drug candidate, PUR0200, which is intended to treat chronic obstructive pulmonary diseases

* New patent covers PUR0200, an inhaled drug made by combining Pulmatrix’s technology platform with tiotropium bromide Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below